More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

Autor: Ketty Peris, Lev V. Demidov, Lars Bastholt, J.-J. Grob, Paul Nathan, M. Banjin, M. Kukushkina, Alexandros Stratigos, A.M. Forsea, A. Ymeri, Matilda Bylaite-Bucinskiene, Christoph Hoeller, A. Zhukavets, V. Todorovic, G. Weinlich, Claus Garbe, K. Putnik, L. Kandolf Sekulovic, Piotr Rutkowski, M. Risteski, K. Kirov, Iris Zalaudek, J. Ocvirk, Reinhard Dummer, D. Herceg, J. Maric-Brozic, Helen Gogas, Ricardo Vieira, Judit Oláh, Ivana Krajsová, N. Babovic, L. De La Cruz Merino, C. Blank, Johan Hansson, Bart Neyns, Axel Hauschild, C. Lebbé

Publikováno v: Kandolf Sekulovic, L, Peris, K, Hauschild, A, Stratigos, A, Grob, J J, Nathan, P, Dummer, R, Forsea, A M, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, G K, Ocvirk, J, Zhukavets, A, Kukushkina, M, De La Cruz Merino, L, Ymeri, A, Risteski, M & Garbe, C 2017, ' More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments ', European Journal of Cancer, vol. 75, pp. 313-322 . https://doi.org/10.1016/j.ejca.2017.01.012

Background. Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europeand esti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f963ef44b2ff1f7ae62a81d631ae3c4
https://portal.findresearcher.sdu.dk/da/publications/08a9e901-9c2e-4d58-beae-d673d2edee93